



Company profile

Dermapharm is a fast-growing manufacturer of branded pharmaceuticals. Founded in 1991, the company is based in Grünwald near Munich. In addition to the main site in Brehna near Leipzig, Dermapharm operates further production, development and sales sites within Europe, primarily in Germany. Dermapharm currently employs more than 2,300 people in 14 countries.


Reasons to invest

1. Clear focus on Germany as a production location
2. Rapidly growing pharmaceutical manufacturer in selected niche markets
3. Own R&D with about 40 ongoing development projects in the pipeline
4. Successful track record in acquisitions
5. Increasing expansion of international presence


Key figures

		3M 2022	3M 2021	2021	2020	2019
Revenue	EUR million	231,6	212,2	942,9	793,8	700,9
Adjusted EBITDA	EUR million	75,1	63,7	351,1	200,7	177,6
Adjusted EBITDA-margin	%	32,4	30,0	37,2	25,3	25,3
Unadjusted EBITDA	EUR million	71,3	62,8	354,4	184,5	168,5
Unadjusted EBITDA-margin	%	30,8	29,6	37,6	23,2	24,0
Operating income	EUR million	58,1	51,8	298,5	136,9	119,5
Earnings before taxes	EUR million	57,4	49,0	293,0	125,3	110,1
Profit or (loss) for the period	EUR million	37,1	36,2	208,9	85,9	77,8
Earnings per share	EUR	0,69	0,67	3,89	1,59	1,43


Revenue by segments (in EUR million)



EBITDA by segments (in EUR million)



Adjusted EBITDA-margin (in %)



2022 guidance

Group revenue growth:

10% to 13%

vs. previous year (EUR 942,9 million)

Group EBITDA growth:

3% to 7%

vs. previous year (EUR 351,1 million)



Dermapharm reports in three segments

Branded pharmaceuticals and other healthcare products

With more than 380 active pharmaceutical ingredients, Dermapharm markets approximately 1,300 marketing authorisations. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.

Herbal extracts

In the "Herbal Extracts" segment, Dermapharm has a globally leading manufacturer of plant extracts and herbal active ingredients for the pharmaceutical, nutraceutical, food and cosmetics industries in the form of the Spanish company Euromed S.A. and the market leader for dronabinol in Germany in the form of the C³ Group.

Parallel import business


Dermapharm's business model also includes a "parallel import business" segment, which is operated under the "axicorp" brand. Based on turnover, axicorp was in the top-5 of the strongest parallel importers in Germany in 2021.

Facts about Dermapharm share


Ticker symbol:	DMP
Ticker Symbol Bloomberg:	DMP:GR
Ticker Symbol Reuters:	DMPG.DE
WKN ISIN:	A2GS5D DE000A2GS5D8
Number of shares:	53,84 Mio.
IPO:	9 February 2018

Shareholder structure

(unchanged since 15 October 2020)



Dermapharm share in comparison



Financial calendar

23 August 2022

Publication of preliminary figures for the 2022 half-year

7 September 2022

Publication of the 2022 half-year report

26 October 2022

Capital Markets Day

Notice:

This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.